Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

NM Navone; WM van Weerden; RL Vessella; ED Williams; Y Wang; JT Isaacs; HM Nguyen; Z Culig; G van der Pluijm; CA Rentsch; RB Marques; CMA de Ridder; L Bubendorf; GN Thalmann; WN Brennen; FR Santer; PL Moser; P Shepherd; E Efstathiou; H Xue; D Lin; J Buijs; T Bosse; A Collins; N Maitland; M Buzza; M Kouspou; A Achtman; RA Taylor; G Risbridger; E Corey

Journal article

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

NM Navone, WM van Weerden, RL Vessella, ED Williams, Y Wang, JT Isaacs, HM Nguyen, Z Culig, G van der Pluijm, CA Rentsch, RB Marques, CMA de Ridder, L Bubendorf, GN Thalmann, WN Brennen, FR Santer, PL Moser, P Shepherd, E Efstathiou, H Xue Show all

Prostate | WILEY | Published : 2018

DOI: 10.1002/pros.23701

Download PDF

Abstract

Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly f..

View full abstract